We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Evaluation of Nutritional Status in Thalassemia Major Patients in Assiut Children Hospital

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03161899
Recruitment Status : Completed
First Posted : May 22, 2017
Last Update Posted : July 30, 2020
Information provided by (Responsible Party):
ARAbdelmonem, Assiut University

Brief Summary:

Thalassemia is a blood disorder passed down through families in which the body makes an abnormal form of hemoglobin. There are 2 main types of thalassemia; Alpha & Beta thalassemia. Alpha thalassemia: occurs when a gene or genes related to the alpha globin protein are missing or mutated.

Beta-thalassemia syndromes are a group of hereditary blood disorders characterized by reduced or absent beta globin chain synthesis. Beta-thalassemias can be classified into:

Silent carrier: completely asymptomatic with normal hematological parameters. Beta-thalassaemia minor (beta-thalassaemia trait): usually asymptomatic; diagnosis is made during a work-up for mild anemia.

Beta-thalassaemia intermedia: usually a similar presentation to beta-thalassaemia major; symptoms are usually less pronounced and the course is usually more insidious.

Beta-thalassaemia major : In which there is complete absence of hemoglobin A

Condition or disease
Thalassemia Major

Detailed Description:

In Egypt beta thalassemia-major is the most common type with carrier rate of 5.3 to ≥9%and 1000 new cases born with beta-thalassemia major per 1.5 million live births per year.

Children born with thalassemia major are normal at birth, but develop severe hemolytic anemia during the first year of life. Symptoms are those of anemia (lethargy, poor feeding, pallor…etc.) failure to thrive and organomegaly. Later on they develop signs of extra medullary hematopoiesis .

Optimal nutritional status is important for growth, immune function, bone health and pubertal development . Various reports suggest the incidence of poor growth ranges from 25% to 75% depending on thalassemia syndrome and severity of disease. This marked growth deficits raise a red flag for any pediatrician to evaluate nutritional status of thalassemic patients and detect possible nutritional deficiencies and associated factors.

Etiology of delayed growth and malnutrition reported in thalassemic patient is multifactorial including :

  1. Nutritional deprivation with or without feeding difficulties arising from fatigue and breathlessness
  2. Increased energy expenditure secondary to hyper metabolism with or without heart failure
  3. Gastrointestinal hypoxia which consequently produces anorexia and malabsorption
  4. Reduction of biosynthetic activity of liver.
  5. Disturbance of the endocrine function
  6. Impaired synthetic hepatic function secondary to hemosiderosis and hepatitis.

The main aim of this study is to assess the nutritional status of thalassemic patient attending Assiut university Children hospital and to determine the factors involved.

Layout table for study information
Study Type : Observational
Actual Enrollment : 246 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Evaluation of Nutritional Status in Patients With Thalassemia Major in Assiut University Children Hospital
Actual Study Start Date : December 15, 2018
Actual Primary Completion Date : May 24, 2020
Actual Study Completion Date : July 20, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Thalassemia

Primary Outcome Measures :
  1. percentage of malnutrition [ Time Frame: 12 month ]
    prevalence of malnutrition among thalassemic children attending assiut university children hospital

Secondary Outcome Measures :
  1. aetiology poor growth [ Time Frame: 12 month ]
    determination of the most common causes responsible for poor growth seen in thalassemic patients

  2. decrease morbidity [ Time Frame: 18 month ]
    decrease morbidity by providing possible strategies for early prevention of the problem of poor growth occurring in patients with thalassemia major

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years to 14 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
all beta thalassemic patients attending the children Hematology Clinic, Children Hospital, Assiut University, during the period of 1st of June 2017 till 31 th of may 2018.

Inclusion Criteria:

  • patients diagnosed to have thalassemia

Exclusion Criteria:

  • patient with any underlaying systemic diseases other than B thalassemia major.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03161899

Layout table for location information
Asmaa Refaat Abdelmonem
Assiut, Egypt
Sponsors and Collaborators
Assiut University
Layout table for investigator information
Principal Investigator: asmaa refaat, MBBCH Assuit , faculty of medicine, egypt
Layout table for additonal information
Responsible Party: ARAbdelmonem, resident doctor of pediatrics, Assiut University
ClinicalTrials.gov Identifier: NCT03161899    
Other Study ID Numbers: ENST
First Posted: May 22, 2017    Key Record Dates
Last Update Posted: July 30, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ARAbdelmonem, Assiut University:
thalassemia - nutrition -growth
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn